IAG Partners with Leading Academics to Provide AI-powered MRI Analysis of Scleroderma
October 23, 2017
IAG, the Image Analysis Group has partnered with the academics from the Faculty of Medicine and Health of the University of Leeds, UK to commercialise proprietary IP and research into imaging biomarkers for scleroderma. The venture has already received initial funding.
Led by Dr. Francesco Del Galdo and in collaboration with Profs Buch and Redmond the Scleroderma Research Programme in Leeds is one of the most comprehensive and multidisciplinary research programmes internationally.
As a result of this partnership an advanced imaging tool for the quantification of the digital artery volume index through non-contrast MRI of the hands will be brought to the market.
IAG will be applying state of the art machine learning to help brining to the clinical research market an operator independent tool for the scleroderma image quantification. It will be an integral part of DYNAMIKA, IAG’s proprietary cloud platform for data management and analysis in clinical trials. The tool will increase the feasibility and the reliability of Scleroderma MRIs, minimising the hands-on time and variability among users. Both feasibility and reliability are required pre-filters for biomarker adoption by OMERACT (Outcome Measure in Rheumatology Consortium). Hence, the development of this tool by IAG in collaboration with Leeds is a pre-requisite for biomarker adoption as an outcome measure by the international community.
“This is a great example of years of academic collaboration resulting in a joint commercial venture. We are delighted to take the best of academic research and translate it into the commercial world for the benefit of patients, while helping our bio-pharma partners to bring novel treatments to market faster,” Dr. Olga Kubassova, CEO of IAG, said in a statement.
Scleroderma is caused by the immune system attacking the connective tissue under the skin and around internal organs and blood vessels. This causes scarring and thickening of the tissue in these areas. There is no cure today. TMR estimates that the global scleroderma diagnostics and therapeutics market will expand at a CAGR of 9.7% from 2016 to 2024 and rise from US$1,633.5m in 2015 to US$3,663.7m by 2024.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin
DYNAMIKA, IAG’s proprietary cloud platform for data management and analysis in clinical trials. DYNAMIKA allows to integrate the disparate information in a clinical trial from all the data sources to provide investors, company’s management and all stakeholders with unparalleled visibility and transparency in the trial process. DYNAMIKA has both a CE Mark and FDA clearance for its image processing algorithms, enabling fast validation and clinical adoption of new imaging biomarkers.